Skip to main navigation
Iovance Biotherapeutics
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn
 
 
  • Home
  • Our Company
    • About Iovance Biotherapeutics
    • Management
    • Board of Directors
    • Research Partners & Collaborators
  • Our Science
    • About TIL
    • Our T-cell Therapy Platforms
    • Scientific Publications & Presentations
    • Next Generation Research
  • Our Technology
    • Iovance Cell
      Therapy Center
    • Manufacturing
    • Intellectual Property
  • Our Pipeline
    • Clinical Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • Careers
    • Current Opportunities
    • Our Culture
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn

Press Releases

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Ownership Summary
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
    • Earnings Estimates
  • Fundamentals
    • Snapshot
    • Trading Statistics
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Ratios
  • Corporate Governance
    • Governance Highlights
    • Committee Composition
Investor Toolkit
  • Print Page
  • RSS
  • Email Alerts
  • Jan 23, 2023 Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
    Acquisition of Worldwide Rights to Proleukin ® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma Positive Clinical Data in
    View
Iovance Biotherapeutics
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn
© 2023 IOVANCE Biotherapeutics, Inc. All Rights Reserved. IOVANCE logo is a trademark owned
by IOVANCE Biotherapeutics, Inc.
  • Privacy Notice
  • Terms of Use
COOKIE NOTIFICATION

This website uses cookies to improve the site and user experience. By continuing to browse the site, you agree to accept our use of cookies. For more information, please review our cookie policy.

Accept